Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer by Yuanlin Wu, Jiandong Zhang, Junjun Zhao, Bin Wang

Get full text

Advancing non-small cell lung cancer treatment: the power of combination immunotherapies by Yuanlin Wu, Guangmao Yu, Ketao Jin, Jun Qian

Get full text

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database by Tingting Jiang, Yanping Li, Ni Zhang, Lanlan Gan, Hui Su, Guiyuan Xiang, Yuanlin Wu, Yao Liu

Get full text

Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States by Guiyuan Xiang, Yueyue Huang, Yueyue Huang, Lanlan Gan, Linning Wang, Yunqi Ding, Yuanlin Wu, Haiyan Xing, Yao Liu

Get full text

Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study by Ni Zhang, Lanlan Gan, Guiyuan Xiang, Jing Xu, Tingting Jiang, Yanping Li, Yuanlin Wu, Rui Ni, Yao Liu

Get full text

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis by Guiyuan Xiang, Yueyue Huang, Ni Zhang, Xinyu Du, Yuanlin Wu, Lanlan Gan, Yanping Li, Tingting Jiang, Yao Liu

Get full text

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021 by Tingting Jiang, Hui Su, Jing Xu, Chen Li, Ni Zhang, Yanping Li, Yuanlin Wu, Rui Ni, Yue Ming, Ziwei Li, Li Li, Yao Liu

Get full text

Protective Role of γδ T Cells in Different Pathogen Infections and Its Potential Clinical Application by Yueshui Zhao, Ling Lin, Zhangang Xiao, Mingxing Li, Xu Wu, Wanping Li, Xiaobing Li, Qijie Zhao, Yuanlin Wu, Hanyu Zhang, Jianhua Yin, Lingling Zhang, Chi Hin Cho, Jing Shen

Get full text